State of the art in benefit-risk analysis: medicines

J. Luteijn, B. White, H. Gunnlaugsdottir, F. Holm, N. Kalogeras, O. Leino, S. Magnusson, G.J. Odekerken-Schröder, M. Pohjola, M.J. Tijhuis, J. Tuomisto, O. Ueland, P.A. McCarron, H. Verhagen

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

Benefit–risk assessment in medicine has been a valuable tool in the regulation of medicines since the 1960s. Benefit–risk assessment takes place in multiple stages during a medicine’s life-cycle and can be conducted in a variety of ways, using methods ranging from qualitative to quantitative. Each benefit–risk assessment method is subject to its own specific strengths and limitations. Despite its widespread and long-time use, benefit–risk assessment in medicine is subject to debate and suffers from a number of limitations and is currently still under development.this state of the art review paper will discuss the various aspects and approaches to benefit–risk assessment in medicine in a chronological pathway. The review will discuss all types of benefit–risk assessment a medicinal product will undergo during its lifecycle, from phase i clinical trials to post-marketing surveillance and health technology assessment for inclusion in public formularies. The benefit–risk profile of a drug is dynamic and differs for different indications and patient groups. In the end of this review we conclude benefit–risk analysis in medicine is a developed practice that is subject to continuous improvement and modernisation. Improvement not only in methodology, but also in cooperation between organizations can improve benefit–risk assessment.
Original languageEnglish
Pages (from-to)26-32
JournalFood and Chemical Toxicology
Volume50
Issue number1
DOIs
Publication statusPublished - 1 Jan 2012

Cite this

Luteijn, J., White, B., Gunnlaugsdottir, H., Holm, F., Kalogeras, N., Leino, O., Magnusson, S., Odekerken-Schröder, G. J., Pohjola, M., Tijhuis, M. J., Tuomisto, J., Ueland, O., McCarron, P. A., & Verhagen, H. (2012). State of the art in benefit-risk analysis: medicines. Food and Chemical Toxicology, 50(1), 26-32. https://doi.org/10.1016/j.fct.2011.06.008